Zonegran + sugar pill
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Binge Eating Disorder Associated With Obesity
Conditions
Binge Eating Disorder Associated With Obesity
Trial Timeline
Aug 1, 2005 → Mar 1, 2009
NCT ID
NCT00221442About Zonegran + sugar pill
Zonegran + sugar pill is a phase 3 stage product being developed by Eisai for Binge Eating Disorder Associated With Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT00221442. Target conditions include Binge Eating Disorder Associated With Obesity.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00221442 | Phase 3 | Completed |
Competing Products
11 competing products in Binge Eating Disorder Associated With Obesity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine + Placebo | Eli Lilly | Approved | 85 |
| Dasotraline + Placebo | Sumitomo Pharma | Phase 2/3 | 65 |
| dasotraline 4mg + dasotraline 6mg + Placebo | Sumitomo Pharma | Phase 3 | 77 |
| Dasotraline | Sumitomo Pharma | Phase 3 | 77 |
| Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml + Placebo | Novo Nordisk | Phase 3 | 76 |
| Solriamfetol + Placebo | Jazz Pharmaceuticals | Approved | 82 |
| Sodium Oxybate | Jazz Pharmaceuticals | Phase 2/3 | 62 |
| Solriamfetol 75mg, 150 mg, or 300 mg | Axsome Therapeutics | Phase 3 | 74 |
| Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo | Axsome Therapeutics | Phase 3 | 74 |
| RDC-0313 (ALKS 33) + Placebo | Alkermes | Phase 2 | 49 |
| ACT-539313 + Placebo | Idorsia | Phase 2 | 47 |